Hosted on MSN7d
Hookipa Pharma to acquire Poolbeg Pharma
The boards of directors of Hookipa Pharma (HOOK) and Poolbeg Pharma announced that they have entered into non-binding ...
Cure Today17d
Epkinly Leads to Responses in Heavily Pretreated Patients With CLL
Cytokine release syndrome (CRS): a condition that occurs when the body overreacts to immunotherapy, which can become life-threatening if not treated immediately. ECOG performance status: a measurement ...
MedPage Today1mon
Promising Results With Epcoritamab Monotherapy in Relapsed/Refractory CLL
Complete responses (CRs) were seen in 43% ... and is associated with low responses to conventional therapies, including immunotherapy in particular," Danilov said during a press briefing at ...
Macrophages, not T cells, may hold key to predicting which melanoma patients are more likely to respond to immunotherapy
An international team of UK and US scientists has discovered that the activity of macrophages—a type of white blood cell that ...
Business Wire1mon
City of Hope Reports Novel Immunotherapy in Clinical Trial Shows Promise for Patients With Relapsed or Difficult to Treat Chronic Lymphocytic Leukemia (CLL)
Dr. Koffman has had no major side effects since the first five weeks of the trial when researchers were still figuring out the proper dosage and countering cytokine release syndrome (CRS ...
Vir Biotechnology Stock Soars On Prostate Cancer Trial Data - Here's Why
Vir Biotechnology's Phase 1 trials reveal promising safety and efficacy for dual-masked T-cell engagers targeting HER2 and ...
Poolbeg Pharma plc (“Poolbeg” or the “Company”) Combination of Poolbeg and HOOKIPA Pharma Inc.
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD ...
Yahoo Finance28d
TuHURA Biosciences, Inc. Enters into Definitive Merger Agreement to Acquire Kineta, Inc.
KVA12123 is a VISTA-blocking immunotherapy in development as a monoclonal ... models or induction of cytokine release syndrome (CRS) in human clinical trials. Through the combination of unique ...
PharmiWeb1mon
Poolbeg Pharma plc presents POLB 001 pre-clinical study data at the 66th American Society of Hematology (ASH) Annual Meeting
The results of this animal study support development of POLB 001 in a Phase 2 clinical study as a prophylactic for the prevention of immunotherapy-induced CRS. The previous successful LPS trial in ...
Business Insider28d
TuHURA Biosciences enters definitive merger agreement to acquire Kineta
KVA12123 is a VISTA-blocking immunotherapy in development as a monoclonal ... inhibition in preclinical models without evidence of CRS in clinical trial participants. KVA12123 has been shown ...